SQI Diagnostics Inc. announced that patient enrollment began for the Company's clinical study for its direct-to-consumer COVID-19 HOME Antibody Test with the data to be used to support its EUA regulatory submission to the U.S. FDA. The clinical study is being conducted in the United States and will analyze blood samples from both COVID-19 positive and negative subjects to meet FDA EUA guidelines. Blood samples are taken by the subjects at home and shipped and tested on SQI's automated sqidlite® system. The clinical study for SQI's COVID-19 HOME Antibody Test is anticipated to conclude in early second quarter 2021.